Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

JOURNAVX

SUZETRIGINE

Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview JOURNAVX is listed in Drugs@FDA under application 219209 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient SUZETRIGINE Form and strength TABLET;ORAL - 50MG Sponsor VERTEX PHARMS INC Submission history Latest submission status date: 2026-01-23 00:00:00.

Structured Monograph

Clinical summary

Approval overview JOURNAVX is listed in Drugs@FDA under application 219209 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient SUZETRIGINE Form and strength TABLET;ORAL - 50MG Sponsor VERTEX PHARMS INC Submission history Latest submission status date: 2026-01-23 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.